Dms 1688

ATTACHMENT

NEW REVISION TO EPON® RESIN 828 MSDS

As part of Shell's ongoing Product Safety efforts, Health and Safety studies are constantly being pursued, reviewed, and evaluated. When information so developed indicates a potential hazard, that information must be included on the Material Safety Data Sheet (MSDS). Shell believes that customers, employees, and the general public have a right to new Health and Safety information even though it may not indicate a hazard. Such information is also included in Shell MSDSs under the heading Section VI, Supplemental Information.

This notice is to let you know that the MSDS on EPON Resin 828 has been revised (copy attached) to include the following new information which now appears in Section VI:

Two-year bioassays in mice exposed by the dermal route to this product, to the diglycidyl ether of bisphenol A (DGEBPA), or to other commercial resins which are composed predominantly of DGEBPA have yielded very limited evidence of weak carcinogenicity. (DGEBPA is a major component (80-85% wt) of EPON Resin 828.) The authors of this work conclude that the renal tumor evidence with EPON Resin 828 "was of no biological importance" and that the resin "is not a systemic carcinogen when applied to the skin of CF1 mice." Based upon this and all other available information, the International Agency for Research on Cancer (IARC) concluded (1988) that DGEBPA was not classifiable as a carcinogen.

Similar language will be added to the MSDSs for other DGEBPA-containing EPON Resin Products.

These changes are based on work performed at Shell International Chemical Company's Tunstall Laboratories in England, our prime location for research on health effects on our products. They recently provided us with some new information on EPON Resin 828. This laboratory applied a new statistical method to previously analyzed test data which has been the basis of our conclusion that EPON Resin 828 and its homologs are not carcinogenic. This new analysis again led the researchers to this conclusion, but revealed weak evidence of

trends in renal (kidney) tumor development in mice exposed by skin contact to EPON Resin 828 and to lymphoreticular tumors on similar exposure to EPIKOTE® Resin 828 (another commercial resin) or to the diglycidyl ether of bisphenol A (DGEBPA).

If you need any additional information, please feel free to contact our Product Safety and Compliance department at (713) 241-0567.